Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data

PURPOSE: Patients with HER2-positive (HER2(+)) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world data to analyze whether pyrotinib affects overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Anwar, Munawar, Chen, Qitong, Ouyang, Dengjie, Wang, Shouman, Xie, Ning, Ouyang, Quchang, Fan, Peizhi, Qian, Liyuan, Chen, Gannong, Zhou, Enxiang, Guo, Lei, Gu, Xiaowen, Ding, Boning, Yang, Xiaohong, Liu, Liping, Deng, Chao, Xiao, Zhi, Li, Jing, Wang, Yunqi, Zeng, Shan, Hu, Jinhui, Zhou, Wei, Qiu, Bo, Wang, Zhongming, Weng, Jie, Liu, Mingwen, Li, Yi, Tang, Tiegang, Wang, Jianguo, Zhang, Hui, Dai, Bin, Tang, Wuping, Wu, Tao, Xiao, Maoliang, Li, Xiantao, Liu, Hailong, Li, Lai, Yi, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401483/
https://www.ncbi.nlm.nih.gov/pubmed/34112711
http://dx.doi.org/10.1158/1078-0432.CCR-21-0474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401483/
https://www.ncbi.nlm.nih.gov/pubmed/34112711
http://dx.doi.org/10.1158/1078-0432.CCR-21-0474

Ejemplares similares